BioCentury
ARTICLE | Clinical News

Talvesta talotrexin: Phase I data

November 13, 2006 8:00 AM UTC

In a dose-escalation Phase I trial in 25 patients, 54 mg/m 2 was the MTD of Talvesta. At that dose, the compound had a mean peak plasma concentration of 17.42 ng/L and the mean plasma concentration at...